Imposing rebates on list prices of drugs that exceed inflation, restructuring Medicare Part D (particularly the catastrophic phase of the outpatient drug benefit), and Medicare negotiations for certain drugs, will have a limited impact on the drug industry, challenging it in unprecedented ways.
Critics Decry Drug Pricing Provisions In Inflation Reduction Act, Say They Will Stifle Innovation
